Neladalkib (TFA)

Neladalkib TFA is the TFA salt form of Neladalkib (HY-156467) . Neladalkib (NVL-655) is an oral ALK inhibitor, the IC50 for Neladalkib in inhibiting ALK is 2.8 nM. Neladalkib promotes cell apoptosis and has anti-tumor activity[1][2].

Product Specifications

Product Name Alternative

NVL-655 (TFA)

UNSPSC

12352005

Target

Anaplastic lymphoma kinase (ALK) ; Apoptosis

Type

Reference compound

Related Pathways

Apoptosis; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/alk-in-27-tfa.html

Purity

99.70

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CCN1C2=C(C(Cl)=N1)CC3=CN(C)N=C3C4=CC=C(F)C=C4[C@H](OC5=C(N)N=CC2=C5)C.OC(C(F)(F)F)=O

Molecular Formula

C25H23ClF4N6O3

Molecular Weight

566.94

References & Citations

[1]Jennifer Anne Green, et al. Methods of treating solid tumor using (19r) -5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1 (24),2 (6),4,8,11,13,15,17,21 (25),22-decaen-22-amine. WO2023196910A1. |[2]Jessica J Lin, et al. NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations. Cancer Discov. 2024 Sep 13:OF1-OF20.